1 Introduction The management of severe aortic stenosis (AS) has undergone significant evolution, with transcatheter aortic valve replacement (TAVR) now the preferred treatment for most patients [ 1234 ], reserving surgical aortic valve replacement (SAVR) for younger patients with longer life expectancy. [ 567 ] Nonetheless, prosthesis-patient mismatch (PPM) presents a persistent risk when the implanted valve's effective orifice area (EOA) is insufficient relative to the patient's body size, negatively impacting cardiac output requirements. [ 8 ] Severe PPM has been linked to increased short- and long-term mortality. [ 7 , 91011121314 ] Compared with SAVR, TAVR has been consistently associated with lower rates of PPM. [ 15161718 ]